Two-Year Clinical Outcomes Between Prediabetic and Diabetic Patients With STEMI and Multivessel Disease Who Underwent Successful PCI Using Drug-Eluting Stents
Restricted accessResearch articleFirst published online January, 2021
Two-Year Clinical Outcomes Between Prediabetic and Diabetic Patients With STEMI and Multivessel Disease Who Underwent Successful PCI Using Drug-Eluting Stents
To evaluate clinical implication of prediabetes, we compared a 2-year major clinical outcome including patient-oriented composite outcomes (POCOs), stent thrombosis (ST), and stroke between prediabetes and diabetes in patients with ST-segment elevation myocardial infarction (STEMI) and multivessel disease (MVD). A total of 4097 patients with STEMI and MVD (normoglycemia [group A: 1001], prediabetes [group B: 1518], and diabetes [group C: 1578]) who received drug-eluting stents were evaluated. Patient-oriented composite outcomes were defined as all-cause death, recurrent myocardial infarction (MI), or any repeat revascularization. The cumulative incidences of POCOs, ST, and stroke were similar between groups B and C. The cumulative incidences of all-cause death (adjusted hazard ratio [aHR]: 1.483; 95% CI: 1.027-2.143; P = .036) and all-cause death or MI (aHR: 1.429, 95% CI: 1.034-1.974; P = .031) were higher in group B than in group A. The cumulative incidences of all-cause death (aHR: 1.563; 95% CI: 1.089-2.243; P = .015), cardiac death (aHR: 1.661; 95% CI: 1.123-2.457; P = .011), and all-cause death or MI were higher in group C than in group A. In conclusion, prediabetes could potentially have a similar impact as diabetes on major clinical outcomes in patients with STEMI and MVD.
RydénLGrantPJAnkerSD, et al.ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European society of cardiology (ESC) and developed in collaboration with the European association for the study of diabetes (EASD). Eur Heart J. 2013;34:3035–87.
2.
HuFBStampferMJSolomonCG, et al.The impact of diabetes mellitus on mortality from all causes and coronary heart disease in women: 20 years of follow-up. Arch Intern Med. 2001;161:1717–23.
3.
National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel iii) final report. Circulation. 2002;106:3143–421.
4.
AliMKBullardKMSaydahSImperatoreGGreggEW. Cardiovascular and renal burdens of prediabetes in the USA: analysis of data from serial cross-sectional surveys, 1988-2014. Lancet Diabetes Endocrinol. 2018;6:392–403.
5.
SinnaevePRStegPGFoxKA, et al.Association of elevated fasting glucose with increased short-term and 6-month mortality in ST-segment elevation and non-ST-segment elevation acute coronary syndromes: the global registry of acute coronary events. Arch Intern Med. 2009;169:402–9.
6.
KolmanLHuYCMontgomeryDGGordonKEagleKAJacksonEA. Prognostic value of admission fasting glucose levels in patients with acute coronary syndrome. Am J Cardiol. 2009;104:470–4.
7.
ArnoldSVLipskaKJLiY, et al.Prevalence of glucose abnormalities among patients presenting with an acute myocardial infarction. Am Heart J. 2014;168:466–70.
8.
KokMMvon BirgelenCSattarN, et al.Prediabetes and its impact on clinical outcome after coronary intervention in a broad patient population. EuroIntervention. 2018;14:e1049–56.
9.
von BirgelenCKokMMSattarN, et al.“Silent” diabetes and clinical outcome after treatment with contemporary drug-eluting stents: the bio-resort silent diabetes study. JACC Cardiovasc Inter. 2018;11:448–59.
10.
CarrisNWMagnessRRLabovitzAJ. Prevention of diabetes mellitus in patients with prediabetes. Am J Cardio. 2019;123:507–12.
11.
NorhammarAMalmbergKDiderholmE, et al.Diabetes mellitus: the major risk factor in unstable coronary artery disease even after consideration of the extent of coronary artery disease and benefits of revascularization. J Am Coll Cardiol. 2004;43:585–91.
12.
LeeSAChoSJJeongMH, et al.Hypoglycemia at admission in patients with acute myocardial infarction predicts a higher 30-day mortality in patients with poorly controlled type 2 diabetes than in well-controlled patients. Diabetes Care. 2014;37:2366–73.
13.
LeeKHJeongMHAhnYK, et al.Gender differences of success rate of percutaneous coronary intervention and short term cardiac events in Korea acute myocardial infarction registry. Int J Cardiol. 2008;130:227–34.
14.
GrechED. ABC of interventional cardiology: percutaneous coronary intervention. II: the procedure. BMJ. 2003;326:1137–40.
15.
American Diabetes Association. Standards of medical care in diabetes--2010. Diabetes Care. 2010;33:S11–S61.
16.
O’GaraPTKushnerFGAscheimDD, et al.2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American college of cardiology foundation/American heart association task force on practice guidelines. Circulation. 2013;127:e362–e425.
17.
ThieleHAkinISandriM, et al.One-year outcomes after PCI strategies in cardiogenic shock. N Engl J Med. 2018;379:1699–710.
18.
JoHSParkJSSohnJW, et al.Culprit-lesion-only versus multivessel revascularization using drug-eluting stents in patients with ST segment elevation myocardial infarction: a Korean acute myocardial infarction registry-based analysis. Korean Circ J. 2011;41:718–25.
19.
Garcia-GarciaHMMcFaddenEPFarbA, et al.Standardized end point definitions for coronary intervention trials: the academic research consortium-2 consensus document. Circulation. 2018;137:2635–50.
20.
KimYHHerAYJeongMH, et al.Comparison between beta-blockers with angiotensin-converting enzyme inhibitors and beta-blockers with angiotensin ii type i receptor blockers in ST-segment elevation myocardial infarction after successful percutaneous coronary intervention with drug-eluting stents. Cardiovasc Drugs Ther. 2019;33:55–67.
21.
BundhunPKWuZJChenMH. Is there any significant difference in stent thrombosis between sirolimus and paclitaxel eluting stents?: a systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore). 2016;95:e2651.
22.
DonahueRPGoldbergRJChenZGoreJMAlpertJS. The influence of sex and diabetes mellitus on survival following acute myocardial infarction: a community-wide perspective. J Clin Epidemiol. 1993;46:245–52.
23.
BautersCLemesleGde GrootePLamblinN. A systematic review and meta-regression of temporal trends in the excess mortality associated with diabetes mellitus after myocardial infarction. Int J Cardiol. 2016;217:109–21.
24.
CuiKLyuSLiuH, et al.Staged complete revascularization or culprit-only percutaneous coronary intervention for multivessel coronary artery disease in patients with ST-segment elevation myocardial infarction and diabetes. Cardiovasc Diabetol. 2019;18:119.
25.
IbanezBJamesSAgewallS, et al.2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European society of cardiology (ESC). Eur Heart J. 2018;39:119–7.
26.
BartnikMRydénLFerrariR, et al.The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on Diabetes and the Heart. Eur Heart J. 2004;25:1880–90.
27.
HuDYPanCYYuJM. The relationship between coronary artery disease and abnormal glucose regulation in China: the China heart survey. Eur Heart J. 2006;27:2573–79.
28.
The BARI Investigators. Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease: the bypass angioplasty revascularization investigation (BARI). Circulation. 1997;96:1761–9.
29.
RodriguesBMcNeillJH. The diabetic heart: metabolic causes for the development of a cardiomyopathy. Cardiovasc Res. 1992;26:913–22.
30.
Pop-BusuiREvansGWGersteinHC, et al.Effects of cardiac autonomic dysfunction on mortality risk in the action to control cardiovascular risk in diabetes (ACCORD) trial. Diabetes Care. 2010;33:1578–84.
31.
HartgeMMKintscherUUngerT. Endothelial dysfunction and its role in diabetic vascular disease. Endocrinol Metab Clin North Am. 2006;35:551–60.
32.
PickupJC. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care. 2004;27:813–23.
33.
JouvenXLemaîtreRNReaTDSotoodehniaNEmpanaJPSiscovickDS. Diabetes, glucose level, and risk of sudden cardiac death. Eur Heart J. 2005;26:2142–7.
34.
StegengaMEvan der CrabbenSNLeviM, et al.Hyperglycemia stimulates coagulation, whereas hyperinsulinemia impairs fibrinolysis in healthy humans. Diabetes. 2006;55:1807–12.
35.
GholapNNAchanaFADaviesMJRayKKGrayLKhuntiK.Long-term mortality after acute myocardial infarction among individuals with and without diabetes: a systematic review and meta-analysis of studies in the post-reperfusion era. Diabetes Obes Metab. 2017;19:364–74.
36.
NedkoffLKnuimanMHungJBriffaTG. Long-term all-cause and cardiovascular mortality following incident myocardial infarction in men and women with and without diabetes: temporal trends from 1998 to 2009. Eur J Prev Cardiol. 2016;23:1273–81.
37.
EngstrømTKelbækHHelqvistS, et al.Complete revascularisation versus treatment of the culprit lesion only in patients with ST-segment elevation myocardial infarction and multivessel disease (DANAMI-3—PRIMULTI): an open-label, randomised controlled trial. Lancet. 2015;386:665–71.
38.
SmitsPCAbdel-WahabMNeumannFJ, et al.Fractional flow reserve-guided multivessel angioplasty in myocardial infarction. N Engl J Med. 2017;376:1234–44.
39.
KimYHHerAYJeongMH, et al.Impact of stent generation on 2-year clinical outcomes in ST-segment elevation myocardial infarction patients with multivessel disease who underwent culprit-only or multivessel percutaneous coronary intervention. Catheter Cardiovasc Inter. 2020;95:E40–55.
40.
KimYHHerAYJeongMH, et al.One-year clinical outcomes between biodegradable-polymer-coated biolimus-eluting stent and durable-polymer-coated drug-eluting stents in STEMI patients with multivessel coronary artery disease undergoing culprit-only or multivessel PCI. Atherosclerosis. 2019;284:102–9.
41.
GillettMJ. International Expert Committee report on the role of the A1c assay in the diagnosis of diabetes. Diabetes Care. 2009;32:1327–34.
42.
NathanDMTurgeonHReganS, Relationship between glycated haemoglobin levels and mean glucose levels over time. Diabetologia. 2007;50:2239–44.
43.
KnudsenECSeljeflotIAbdelnoorM, et al.Abnormal glucose regulation in patients with acute ST-elevation myocardial infarction-a cohort study on 224 patients. Cardiovasc Diabet. 2009;8:6.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
